Table 5.
Odds ratios (OR) and 95 % CI for association of serum folate concentration with prostate cancer and according to folate metabolic pathway gene polymorphisms
| Cases/controls | Adjusteda OR (95 % CI) tertiles of serum folate (nmol/L) | pintϕ | |||
|---|---|---|---|---|---|
| 1 (2.9–7.4) | 2 (7.5–11.0) | 3 (11.1–24.0) | |||
| MTHFR A1298C | |||||
| Total prostate cancerb | 199/202 | ||||
| AA | 137/151 | (ref.) | 3.82 (1.68–8.67) | 6.33 (2.90–13.85) | 0.257 |
| AC + CC | 62/51 | 2.09 (0.66–6.68) | 2.49 (0.78–7.97) | 11.31 (4.22–30.37) | |
| MTHFR C677T | |||||
| Total prostate cancerb | 202/206 | ||||
| CC | 157/164 | (ref.) | 2.72 (1.21–6.12) | 6.75 (3.19–14.27) | 0.83 |
| CT + TT | 45/42 | 1.07 (0.33–3.45) | 3.48 (1.25–9.70) | 5.74 (2.01–16.33) | |
| MTRR A66G | |||||
| Total prostate cancerb | 195/203 | ||||
| AA | 111/120 | (ref.) | 3.40 (1.38–8.36) | 4.39 (1.85–10.40) | 0.143 |
| AG + GG | 84/83 | 0.72 (0.23–2.28) | 2.06 (0.76–5.64) | 7.86 (3.20–19.35) | |
| MTR A2756G | |||||
| Total prostate cancer b | 199/205 | ||||
| AA | 97/99 | (ref.) | 3.33 (1.22–9.09) | 5.01 (1.99–12.60) | 0.628 |
| AG +GG | 102/106 | 0.93 (0.32–2.72) | 2.68 (1.02–6.99) | 6.78 (2.69–17.07) | |
aModels adjusted for age and BMI as continuous, education (primary or less, secondary or higher), family history of prostate cancer (no/yes), vitamin use (no/yes), and smoking (non-smoker, ex-smoker, current smoker)
b7 cases—Gleason scores unknown
ϕ p value for the interaction